YS Biopharma Co., Ltd. (YS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Beijing, China. The current CEO is Hui Shao.
YS has IPO date of 2021-08-05, 773 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $192.09M.
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
